Carlsmed (CARL) Corporate presentation summary

Mission and business overview

• Aims to improve outcomes and reduce healthcare costs in spine surgery through an AI-enabled, integrated technology platform spanning pre-op, intra-op, and post-op phases.

• Rapidly scaling with published clinical validation, premium reimbursement, and a near-term path to profitability.

Market opportunity

• U.S. spine fusion market includes ~800,000 procedures annually, with lumbar and cervical segments representing $13B and $6B addressable markets, respectively.

Technology platform and clinical impact

• The Myaprevo ecosystem offers advanced 3D planning, personalized device design, and post-op analytics for both lumbar and cervical procedures.

• Peer-reviewed data shows a 74% reduction in revision rates at 2 years for patients using personalized implants versus stock devices.

• AI-driven planning and analytics enhance surgical precision and postoperative assessment.